Sure would have been nice to conduct a larger tri

Quote:

---

Sure would have been nice to conduct a larger trial. Perhaps this is why smaller biotechs have trouble getting over the finish line.

---

This exact statement is why I’ll probably never invest in a small pre-revenue biotech again. A BP would have run a trial last summer of 3000 patients and we would have full approval by now. A small biotech run ing on financial fumes cannot pull off a trial big enough for the math-obsessed BP-bias of the FDA.